Crossmark

Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients

Crossref DOI link: https://doi.org/10.1016/j.medcle.2024.03.018

Published Print: 2024-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Marti-Pastor, Marc

Bou-Monterde, Ricardo

Ciancotti-Oliver, Lucia

Alcover-Pons, Marta

Amorós Cantero, Aurora

Sánchez-Lopezosa, Raquel

Montañana-Rosell, Neus
License Information

Text and Data Mining valid from 2024-09-01

Text and Data Mining valid from 2024-09-01

stm-asf valid from 2024-09-01

stm-asf valid from 2024-09-01

stm-asf valid from 2024-09-01

stm-asf valid from 2024-09-01

stm-asf valid from 2024-09-01
More Information

This article is maintained by: Elsevier

Article Title: Effectiveness of tixagevimab/cilgavimab in reducing SARS-CoV-2 infections, hospitalizations and mortality in inmunocompromised patients

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2024.03.018

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2024.03.013

Content Type: article

Copyright: © 2024 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.